肺癌患者血浆中基质金属蛋白酶抑制剂2蛋白水平及其临床意义

doi:10.3969/j.issn.1004-616x.2013.03.013

癌变·畸变·突变

肺癌患者血浆中基质金属蛋白酶抑制剂2蛋白水平及其临床意义

杨磊¹,吴永凯²,韩廼珺¹,孙克林²,程书钧¹,高燕宁^1,肖汀^1，*

( 1. 中国医学科学院北京协和医学院肿瘤研究所“癌发生及预防分子机理”北京市重点实验室，北京 100021；2. 中国医学科学院北京协和医学院肿瘤医院胸外科，北京 100021 )

收稿日期:2012-11-12 修回日期:2013-03-21 出版日期:2013-05-30 发布日期:2013-05-30
通讯作者: 肖汀，E-mail：xiaot@cicams.ac.cn
作者简介:杨磊 (1984- )，男，山东人，博士研究生，研究方向：恶性肿瘤发生发展的分子机理。E-mail：yl6649084@ 163.com
基金资助:
全国优秀博士学位论文作者专项资金资助项目 (2007B68)，国家自然科学基金项目 (30930042)

TIMP2 plasma protein level and its clinical significance in lung cancer patients

YANG Lei¹，WU Yong-kai²，HAN Nai-jun¹，SUN Ke-lin²，CHENG Shu-jun¹，GAO Yan-ning²，XIAO Ting¹，*

(1. Beijing Key Laboratory for Carcinogenesis and Cancer Prevention, Cancer Institute, Peking Union Medical College & Chinese Academy of Medical Sciences, Beijing 100021; 2. Department of Thoracic Surgery, Cancer Institute, Peking Union Medical College & Chinese Academy of Medical Sciences, Beijing 100021, China)

Received:2012-11-12 Revised:2013-03-21 Online:2013-05-30 Published:2013-05-30
Contact: XIAO Ting，E-mail：xiaot@cicams.ac.cn

摘要/Abstract

摘要：

目的：检测基质金属蛋白酶抑制剂2 (tissue inhibitor of metalloproteinases 2，TIMP2)在肺癌患者血浆中的蛋白水平及其临床意义。方法：通过对214例血浆样本，包括114例肺癌患者、100例健康人，采用酶联免疫吸附试验 (enzyme linked immunosorbent assay，ELISA)进行检测，测定TIMP2蛋白的血浆浓度，检验其诊断肺癌的敏感性和特异性。结果：ELISA检测结果显示，肺癌患者血浆中TIMP2蛋白浓度为 (74.56±16.70) ng/mL，显著低于正常对照人群 (170.98±48.61) ng/mL (P<0.01)。且TIMP2蛋白在晚期 (Ⅲ+Ⅳ期)肺癌患者血浆中的水平 (81.57±15.62) ng/mL显著高于早期 (Ⅰ+Ⅱ期)肺癌患者 (69.16±15.63) ng/mL (P<0.01)；在肿瘤直径小于或等于3 cm肺癌患者血浆中TIMP2蛋白水平显著低于肿瘤直径大于3 cm的肺癌患者 (P<0.01)，并且与肺癌的远处转移相关 (P<0.01)。当cutoff值定为103.29 ng/mL时，TIMP2检测肺癌的敏感性为97.4%，特异性为82.8%。结论：检测血浆中TIMP2的蛋白水平有助于肺癌的诊断。

关键词: 肺癌, 基质金属蛋白酶抑制剂2, 酶联免疫吸附试验, 血浆, 肿瘤标志

Abstract:

OBJECTIVE: To detect the plasma protein levels of tissue inhibitor of metalloproteinases 2 (TIMP2) in lung cancer patients and healthy controls，and analyze its clinical significance. METHODS：Plasma TIMP2 level in 114 patients with primary lung cancer and 100 healthy subjects were measured by an enzyme immunoassay (ELISA). RESULTS：The plasma level of TIMP2 in patients with primary lung cancer (74.56±16.70) ng/mL was significantly lower than the healthy controls (170.98±48.61) ng/mL (P<0.01). The TIMP2 level in stage Ⅲ+Ⅳ(81.57±15.62) ng/mL were significantly higher than those in stage Ⅰ+Ⅱ(69.16±15.63) ng/mL (P<0.01). The plasma TIMP2 levels were elevated in the patients with tumor >3 cm (P<0.01)，and correlated with distant metastasis (P<0.01). When the TIMP2 cutoff value was set to 103.29 ng/mL，sensitivity of lung cancer detection was 97.4%， and specificity was 82.8%. CONCLUSION：Measurement of plasma level of TIMP2 protein may contribute to the diagnosis of lung cancer.

Key words: lung cancer, tissue inhibitor of metalloproteinases 2, enzyme linked immunosorbent assay, plasma, tumor marker

杨磊,吴永凯,韩廼珺,孙克林,程书钧,高燕宁,肖汀. 肺癌患者血浆中基质金属蛋白酶抑制剂2蛋白水平及其临床意义[J]. 癌变·畸变·突变, doi: 10.3969/j.issn.1004-616x.2013.03.013.

YANG Lei，WU Yong-kai，HAN Nai-jun，SUN Ke-lin，CHENG Shu-jun，GAO Yan-ning，XIAO Ting. TIMP2 plasma protein level and its clinical significance in lung cancer patients[J]. Carcinogenesis, Teratogenesis & Mutagenesis, doi: 10.3969/j.issn.1004-616x.2013.03.013.

参考文献

[1] Cersosimo RJ. Lung cancer：a review[J]. Am J Health Syst Pharm，2002，59 (7)：611-642.

[2] Martin J，Ginsberg RJ，Venkatraman ES，et al. Long-term results of combined-modality therapy in resectable non-small-cell lung cancer[J]. J Clin Oncol，2002，20 (8)：1989-1995.

[3] Xiao T，Ying WT，Li L，et al. An approach to studying lung cancer-related proteins in human blood[J]. Mol Cell Proteomics， 2005，4 (10)：1480-1486.

[4] Jiang Y，Goldberg ID，Shi YE. Complex roles of tissue inhibitors of metalloproteinases in cancer[J]. Oncogene，2002，21 (14)： 2245-2252.

[5] Pennanen H，Kuittinen O，Turpeenniemi-Hujanen T. Plasma MMP-2-TIMP-2 complex levels measured during follow-up predict a risk of relapse in patients with malignant lymphoma[J]. Eur J Haematol，2008，80 (1)：46-54.

[6] Peterson NB，Beeghly-Fadiel A，Gao YT，et al. Polymorphisms in tissue inhibitors of metalloproteinases-2 and -3 and breast cancer susceptibility and survival[J]. Int J Cancer，2009，125 (4)：844-850.

[7] Zhang Y，Xu B，Liu Y，et al. The ovarian cancer-derived secretory/releasing proteome：A repertoire of tumor markers[J]. Proteomics，2012，12 (11)：1883-1891.

[8] Nuttall RK，Sampieri CL，Pennington CJ，et al. Expression analysis of the entire MMP and TIMP gene families during mouse tissue development[J]. FEBS Lett，2004，563 (1/2/3)：129-134.

[9] Kessenbrock K，Plaks V，Werb Z. Matrix metalloproteinases： regulators of the tumor microenvironment[J]. Cell，2010，141 (1)：52-67.

[10] Pennanen H，Kuittinen O，Turpeenniemi-Hujanen T. Plasma MMP-2-TIMP-2 complex levels measured during follow-up predict a risk of relapse in patients with malignant lymphoma[J]. Eur J Haematol，2008，80 (1)：46-54.

[11] Cruz-Munoz W，Khokha R. The role of tissue inhibitors of metalloproteinases in tumorigenesis and metastasis[J]. Crit Rev Clin Lab Sci，2008，45 (3)：291-338.

[12] Li H，Lindenmeyer F，Grenet C，et al. AdTIMP-2 inhibits tumor growth，angiogenesis，and metastasis，and prolongs survival in mice[J]. Hum Gene Ther，2001，12 (5)：515-526.

[13] Guedez L，Jensen-Taubman S，Bourboulia D，et al. TIMP-2 targets tumor-associated myeloid suppressor cells with effects in cancer immune dysfunction and angiogenesis[J]. J Immunother， 2012，35 (6)：502-512.

[1]	刘晓霞, 李卫霞, 李志加, 苏镇军, 段晓辉, 韩维文, 王云晓, 贺晓磊, 吕林林, 贾金海. 血清谷胱甘肽过氧化物酶与晚期非小细胞肺癌患者临床病理指标及预后的相关性[J]. 癌变·畸变·突变, 2021, 33(4): 286-290,295.
[2]	王熙凯, 孟庆贺, 高燕鲁. miR-223-3p通过调控ECT2诱导非小细胞肺癌细胞凋亡的实验研究[J]. 癌变·畸变·突变, 2021, 33(3): 187-192.
[3]	赵俊伟, 华辰凤, 尚平平, 谢复炜, 李翔. 亚砷酸As (Ⅲ)诱导人肺癌A549细胞氧化应激反应的实验研究[J]. 癌变·畸变·突变, 2021, 33(1): 28-31.
[4]	赵子慧, 王绪华. 非小细胞肺癌伴随诊断的研究进展[J]. 癌变·畸变·突变, 2021, 33(1): 66-71,76.
[5]	杜强, 姚义勇, 曾刚. 基于TCGA数据库分析ASPM在肺腺癌中的表达及临床意义[J]. 癌变·畸变·突变, 2020, 32(6): 457-463.
[6]	刘晓霞, 李卫霞, 苏镇军, 贾金海, 段晓辉, 李志加, 贺晓磊, 吕林林, 刘睿, 王云晓. 晚期非小细胞肺癌病理特征及放化疗联合治疗疗效与患者血清超氧化物歧化酶的关系[J]. 癌变·畸变·突变, 2020, 32(5): 350-354.
[7]	邵俊国, 焦文静, 王雪晓, 张金艳, 马鸣. miR-429和Bmi-1 mRNA在肺癌组织中的表达及其临床意义[J]. 癌变·畸变·突变, 2020, 32(5): 369-373.
[8]	张凡, 刘广超, 张之晗, 刘方芳, 谢琪, 高淑清. 生酮饮食对人肺癌细胞裸鼠皮下移植瘤生长的影响[J]. 癌变·畸变·突变, 2020, 32(4): 286-291.
[9]	应伟, 王兴远, 江波, 周伟. miR-146a多态性与非小细胞肺癌易感性的研究[J]. 癌变·畸变·突变, 2019, 31(3): 222-226.
[10]	马鸣, 焦文静, 王延海, 颜晰, 张超, 张金艳. 弥漫大B细胞淋巴瘤患者血清IL-24及IL-6浓度检测的临床意义[J]. 癌变·畸变·突变, 2019, 31(3): 227-230.
[11]	朱嘉微, 胡箫, 王希君, 王雅茹, 冯林, 肖汀. Skp1蛋白在非小细胞肺癌组织和外周血中的表达水平及其临床意义[J]. 癌变·畸变·突变, 2019, 31(2): 89-95.
[12]	吴雯, 李萍, 左然, 曾庆波, 吴德生, 谢妮, 龙鼎新, 袁建辉. DNA甲基转移酶3B-149C>T多态性与致癌风险相关性的Meta分析[J]. 癌变·畸变·突变, 2019, 31(2): 102-110.
[13]	崔宏伟, 苏秀兰. 胃癌干细胞在胃癌靶向治疗中的研究进展[J]. 癌变·畸变·突变, 2018, 30(6): 490-493.
[14]	马帮靖, 郝翔麟, 韩飞, 陈洪强, 刘晋祎, 曹佳, 张爱华. SOX30基因调控桥粒基因DSC3抑制肺腺癌的增殖与迁移[J]. 癌变·畸变·突变, 2018, 30(3): 165-170,175.
[15]	吴异兰, 王晗. 白藜芦醇对肺癌紫杉醇耐药细胞的增殖抑制作用及其机制[J]. 癌变·畸变·突变, 2018, 30(3): 200-203,208.

肺癌患者血浆中基质金属蛋白酶抑制剂2蛋白水平及其临床意义

TIMP2 plasma protein level and its clinical significance in lung cancer patients

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价